CY3, a blend of Liothyronine, Clenbuterol and Yohimbine, is produced by Dragon Pharma. It is available in 100 tabs packaging consisting of Clenbuterol in 37mcg, Liothyronine in 25mcg, and Yohimbine in 5.4mg with International delivery service. CY3 is a blend of stimulants, combined together to enhance the results of the steroids during the cutting cycle. These three stimulants work well together as a blend because of their differing absorption rates and distinctive bioavailability. These stimulants are successful individually but when they are combined, the results are instantly apparent. Clenbuterol has been in use to treat asthma related symptoms. It acts as a thermogenic which can increase the body’s temperature, thus, resulting in fat burn. Meanwhile, Yohimbine has always been in use to burn fat by increasing the level of adrenaline in the body. On the other hand, Liothyronine as well works at cellular level by increasing the process of breaking down protein, carbs and fats, it provides instant boost of stamina and power to help the bodybuilder perform better. It would also significantly shred a lot of fat and make room for the muscles to grow. Therefore, combining these three together creates a powerful dose for an instant and effective cutting cycle.
CY3 offers following benefits of three powerful fat burning steroids such as:
– Increases Metabolism
– Develop Muscle Mass
– Enhance Body Strength
– Weight Loss
– Treats Erectile Dysfunction
– Boost Athletic Performance
– Boosts the Process of Thermogenesis
– Prompts Lipolysis Effect
– Increased Heart Rate and Blood Flow
– Excellent Fat Burner
There is no specifically recommended dosage required but it is important that it should not be prolonged for more than 8 weeks as it can result in diverse side effects. Consult your coach who is aware of your specific body needs and then he or she can help you figure out your ideal dosage. It is highly recommended for novice athletes to consult an expert before starting any steroid cycle. It is mandatory to go on post cycle therapy after a cycle of CY3.